ABSTRACT
Nilotinib is a second-generation tyrosine kinase inhibitors that has been approved for the first-line treatment of chronic phase chronic myeloid leukemia, based on the results of a prospective randomized study of nilotinib vs. imatinib (ENESTnd). Apart from this registration study, very few data are currently available on nilotinib first-line. We report here the long-term, 6-year, results of the first investigator-sponsored, GIMEMA multicenter phase II, single-arm, trial with nilotinib 400 mg twice daily as first-line treatment in 73 chronic-phase chronic myeloid leukemia patients. Six-year overall survival and progression-free survival were 96%, with one death after progression to blast phase. At 6 years, 75% of the patients were still on nilotinib. The cumulative incidence of major molecular response was 98%; only one patient had a confirmed loss of major molecular response. The cumulative incidence of deep molecular response (MR 4.0) was 76%. Deep molecular response was stable (≥ 2 years) in 34% of these patients. Cardiovascular adverse events, mainly due to arterial thrombosis, occurred in 11/73 patients (15%), after 24 to 76 months of therapy. They were more frequent in elderly patients, and in those with baseline cardiovascular risk factors.
None was fatal, although there was a relevant morbidity. This is the study with the longest follow-up of a high dose nilotinib (400 mg twice daily), highlighting the high efficacy and the cardiovascular toxicity of the drug (CTG.NCT.00481052).
INTRODUCTION
Nilotinib is a derivative of imatinib with greater potency and specificity against the tyrosine kinase activity of BCR-ABL1, the leukemogenic protein of chronic myeloid leukemia (CML) 1 . A randomized, phase III, study (ENESTnd) showed that in newly diagnosed, chronic phase (CP), chronic myeloid leukemia (CML), nilotinib, both at 300 mg and 400 mg twice daily, induced more and deeper molecular responses than imatinib 400 mg once daily 2 . On the basis of this study, nilotinib was approved for the first-line treatment of CML at the dose of 300 mg twice daily. The latest update of ENESTnd, with up to 5 years of follow-up, confirmed the high rates of deep molecular response, showed a slightly better progression-free survival (PFS), and no difference in overall survival (OS), as compared to imatinib 3, 4 . Cardiovascular toxicity was not pointed out initially 2 , but was reported in subsequent analyses [3] [4] [5] [6] . So far, only two small, single-arm, studies of nilotinib frontline (400 mg twice daily) have been published by independent investigators 7, 8 . These reports, with a short follow-up (median less than 18 months), showed that nilotinib induced high and fast response rates. Later on, some cardiovascular adverse events (CVAEs), mainly atherosclerotic (AAE), and particularly peripheral arterial occlusive disease (PAOD) [9] [10] [11] [12] [13] [14] , were reported in patients treated with nilotinib, in second or third line, raising concern on the long-term safety of the drug. Currently the GIMEMA study has the longest follow-up with nilotinib, but only early data have been so far published, in 2009 7 .
Here we report the results, efficacy and safety, with a minimum follow-up of 6 years. Guidelines for dose adaptation and for treatment discontinuation were already described in details 7 . The study protocol was approved by the ethic committees of all participating centers and was conducted in accordance with the Declaration of Helsinki.
METHODS

Seventy
All patients gave written informed consent. Main exclusion criteria were a performance status ≥ 2, uncontrolled serious medical conditions, and prior treatment with imatinib.
The molecular response (MR) was evaluated on peripheral blood every three months until a major MR (MMR; MR 3.0) was achieved and confirmed, then at least every 6 months. MMR was assessed and expressed according to the international scale (IS), as BCR-ABL1 transcripts level ≤ 0.1%, corresponding to a 3-log decrease from the IS standard, in samples with more than 10,000 ABL1 copies. MR 4.0 was defined as a BCR-ABL1 transcripts level ≤ 0.01%, corresponding to a 4-log reduction, in samples with more than 10,000 ABL1 copies 15 . Stable MR 4.0 was defined by at least 5 evaluations with MR 4.0, with no value > 0.01%, during the last 2 years of treatment.
Molecular tests were performed in one center (Bologna, Italy) until other GIMEMA centers were standardized for the IS. Mutational screening of the BCR-ABL1 kinase domain was done using conventional Sanger sequencing as previously reported 16 , only in case of resistance or progression. The baseline relative risk was calculated using Sokal, EURO, and EUTOS [17] [18] [19] were identified at baseline, prior to nilotinib treatment, according to medical history, and no specific suggestion for their management was provided in the protocol. Since this study was designed before the publication of data evidencing the cardiovascular toxicity of nilotinib, no serum lipids evaluation was planned in the protocol (thus potentially leading to an underestimation of hypercholesterolemia), and no information on tobacco abuse was collected. Statistics was descriptive. The cumulative probabilities of the events, and survival, were estimated by the Kaplan-Meier method.
RESULTS
Patients
The baseline characteristics of the patients are shown in Table 1 . Few patients were at high risk: Sokal 14%, EURO 1%, and EUTOS 3%. The median age was 51 years, with 27% of the patients aged 65 years or more. Thirty-six per cent of patients had one or more CV risk factors: hypertension 19%, obesity 18%, diabetes mellitus 8%, prior CV disease 4%, and hypercholesterolemia 4%.
Outcome and patient disposition
No patient was lost to follow-up, which ranges between 60 and 82 months (median 75 months). The 6-year overall survival was 96% (Figure 1 ). One patient progressed to BP on therapy, at 6 months, and died of leukemia. Other two patients died in remission, while on nilotinib: one with dementia (75 years old), and one of congestive heart failure (90 years old). Apart from these 3 patients, 13 patients discontinued nilotinib: they are now on imatinib (6 patients), or dasatinib (3 patients), or in a trial of treatment-free remission (TFR) (4 patients). Adverse events were the main reason for nilotinib discontinuation (11 patients, 15%): CV AEs in 8 patients (PAOD in 4, carotid stenosis in 2, angina pectoris in one, and atrial fibrillation in one), and recurrent grade 3 or 4 lipase elevation in 3 patients. At last contact, 55 patients (75%) were still on nilotinib, of whom 67% at doses of 300 mg twice daily, 26% at 400 mg once daily; and 7% at 300 mg once daily ( Table 2 ).
Molecular response
Molecular response is shown in Figure 2 . The cumulative 6-year probability of 
DISCUSSION
This final report of a prospective, multicenter, investigator-sponsored, single arm study with a minimum follow-up of 6 years, provides independent data on the rate, the depth, and the stability of the molecular response, on safety (particularly, the long-term CV safety), and on the long-term outcome of front-line treatment with nilotinib in newly diagnosed, CP, CML.
All patients but one responded, and all patients but three became optimal responders according to ELN 2013 recommendations 20 . Thirty-six of 73 (49%) patients were in MR 4.0 at last contact. Of all 73 patients, 18 (24%) were in stable MR 4.0, and were therefore eligible for a trial of treatment discontinuation. Actually, 6 patients are enrolled in such a trial. One patient progressed to BP on therapy, with a T315I mutation. The particularly low rate of progression to BP observed in this study might be partially determined by the low proportion of high Sokal risk patients (14%). Indeed, the progression-free survival (96% at 6 years) is similar to that observed in some trials with front-line imatinib, in the subset of not high-risk patients 21 , or in those with a low proportion of high-risk patients 22 .
Two patients, 75 and 90 years old, died of other causes, while being in MMR. The 6-year overall survival was 96%. Due to some degree of patients' selection, similarly to what occurs in many clinical trials, the median age at CML diagnosis in this study was lower than that reported in most epidemiologic registries, and, possibly, contributed to the high overall survival observed.
Overall, 75% of the patients were still on nilotinib at 6 years. Fifteen per cent (11/73) of patients experienced clinically relevant atherosclerotic AEs (AAEs). None died, but there was a relevant morbidity: two patients underwent the amputation of a lower limb, and four of them an angioplasty for coronary disease.
To compare the efficacy and safety data of this study with the corresponding data of the ENESTnd trial, it must be considered that in the latter there were two cohorts, one at 300 mg twice daily and one at 400 mg twice daily, the number of patients was higher (282 and 281, respectively), the proportion of Sokal high-risk patients was higher (28%), the age was lower (median 46-47 years), and the follow-up was slightly shorter (median 5 years) [2] [3] [4] [5] [6] . Taking into account these differences, the proportion of patients still on nilotinib at 5 years was 60% (at 300 mg twice daily) and 62% (at 400 mg twice daily) in ENESTnd vs. 75% in this study. The cumulative probability of achieving MR 4.0 was 66% (at 300 mg twice daily) and 63% (at 400 mg twice daily) in ENESTnd vs. 76% in this trial. The rate of progression to BP was 3.5% (at 300 mg twice daily) and 2.1% (at 400 mg twice daily) in ENESTnd vs. 1.3% in this study. The rate of deaths by any cause was 6.4% (at 300 mg twice daily) and 3.5% (at 400 mg twice daily) in ENESTnd vs. 4.1% in this trial. The rate of CVAEs was 8% (at 300 mg twice daily) and 13% (at 400 mg twice daily) in ENESTnd vs. 15% in this study. Overall, the results of this smaller clinical trial are well in line with the results of the ENESTnd study for efficacy. For safety, the initial nilotinib dose (400 mg twice daily) and the more advanced age of the patients likely account for a higher rate of CVAEs. It should not be overlooked that the frequency of CVAEs, as reported in the ENESTnd and in this trial, may be lower than that reported in other studies, where the analysis was retrospective, and many patients had prior treatment with other TKIs 9-14 . However, the rate of CVAEs with the initial dose of 400 mg twice daily remains significant, and supports the use of the lower dose of 300 mg twice daily, as it is currently registered for the front-line treatment of CP CML.
In conclusion, this independent study of nilotinib in the first-line treatment of newly diagnosed CP CML highlights the rapid and high anti-leukemic efficacy of this TKI and warns that in patients with cardiovascular risk factors, and particularly in the elderly patients, the treatment can favor the development of clinically relevant, potentially disabling and life-threatening, cardiovascular complications, especially atherosclerotic complications. The balance between efficacy and safety will depend on the characteristics of the patient and on the goal of therapy, whether it is limited to survival or it is addressed, more ambitiously, to the achievement of a treatment-free remission.
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